Neos Therapeutics’ Controlled-Release ADHD Drug Get FDA Approval

08:11 EDT 20 Jun 2017 | Xconomy

Dallas—The FDA late Monday approved Neos Therapeutics’ controlled-release version of an old ADHD therapy, methylphenidate. Neos (NASDAQ: NEOS) says its formulation of methylphenidate (Cotempla XR-ODT) is the first methylphenidate tablet designed to deliver the medication in a gradual manner over time—instead of all at once—and is able to orally disintegrate on the tongue to treat attention-deficit/hyperactivity […]

Original Article: Neos Therapeutics’ Controlled-Release ADHD Drug Get FDA Approval


More From BioPortfolio on "Neos Therapeutics’ Controlled-Release ADHD Drug Get FDA Approval"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...